1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Allgens Medical Technology Co. Ltd.

Allgens Medical Technology Co. Ltd.

688613.SS
Allgens Medical Technology Co. Ltd.CN flagShanghai Stock Exchange
14.57
CNY
+0.10
- -
2.00BMarket Cap
Allgens Medical Technology Co. Ltd.
688613.SS
(Shanghai Stock Exchange)

Recent

price

14.57

P/E

ratio

- -

div

yld

- -

ROIC.AI

2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
1.13
1.27
1.69
1.84
1.97
1.83
1.71
1.46
1.62
1.98
Revenue per Share
0.29
0.34
0.68
0.89
1.01
0.71
0.41
-0.09
0.1
-0.13
Basic EPS, GAAP
0.03
-0.2
0.11
0.28
0.57
0.42
0.23
-0.23
0.08
-0.16
Free Cash Flow per Basic Share
- -
- -
0.02
0.01
0.01
0.3
0.13
0.08
0.02
0.1
Dividend per Share
0.16
0.44
1.05
1.83
2.71
2.78
3.09
2.77
2.9
3.83
Book Value per Share
3.76
4.36
5.38
6.26
10.42
9.71
10.44
9.74
10.11
13.39
Tangible Book Value per Share
81
97
100
100
120
134
132
141
138
104
Basic Weighted Avg Shares
91
124
169
184
236
245
226
206
224
206
Sales/Revenue/Turnover
30.39
27.29
100
54.09
51.15
33.94
14.51
-8.38
-1.7
-8.91
Operating Margin (%)
4
6
7
13
13
18
18
18
22
- -
Depreciation Expense
24
33
68
89
121
95
54
-13
14
-14
Net Income, GAAP
14.33
19.69
13.89
14.66
10.59
4.68
- -
- -
22.67
536.26
Effective Tax Rate (%)
25.75
26.67
40.21
48.4
51.17
38.82
23.95
-6.15
6.19
-6.76
Profit Margin (%)
250
309
403
482
1,066
1,094
1,150
1,144
1,142
1,142
Working Capital
- -
- -
44
52
62
46
48
46
11
10
LT Debt
312
452
564
652
1,271
1,326
1,404
1,420
1,447
1,444
Total Equity
- -
7.08
27.22
12.73
10.42
5.78
- -
- -
-0.2
- -
Return on Invested Capital (%)
- -
111.66
60.79
40.84
36.2
22.64
- -
- -
4.35
0.03
Return on Capital (%)
- -
118.69
92.12
61.83
47.62
27.33
13.87
-3.17
3.5
-3.39
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
7
3
37
LT Borrowings
41
41
8
LT Finance Leases
5
6
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
136
136
137
Market Capitalization
2,503
1,652
1,991

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
1,196
1,221
1,228
Cash, Cash Equivalents & STI
1,052
1,038
1,057
Accounts Receivable, Net
67
69
52
Inventories
55
94
96
Total Current Liabilities
52
66
86
Payables & Accruals
- -
- -
- -
ST Debt
7
3
37
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
21.66%
1.93%
Free Cash Flow
- -
-53.4%
-131.98%
Net Income, GAAP
- -
-72.21%
-209.3%
Sales/Revenue/Turnover
- -
4.85%
8.59%
Total Cash Common Dividend
- -
590.9%
-78.84%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
47
53
48
58
206
2025
42
58
68
- -
224
2026
49
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.05
- -
- -
- -
-0.09
2025
0.01
- -
- -
- -
0.1
2026
0.01
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.08
2025
0.01
- -
- -
- -
0.02
2026
- -
- -
- -
- -
- -
Similar Companies
Brighter AB (publ) (BRIG.ST)
Neola Medical AB (publ) (NEOLA.ST)
NeoDynamics AB (publ) (NEOD.ST)
Creo Medical Limited (CREO.L)
Paragon 28, Inc. (FNA)
CLASSYS Inc. (214150.KQ)
Business
Allgens Medical Technology Co., Ltd. Allgens Medical Technology CO., LTD. (688613.SS) engages in the research, development, production, and sale of high-end implantable medical devices and biomedical materials for tissue regeneration and repair, primarily biomimetic mineralized collagen artificial bone repair products; its main offerings include Igium Gold and BonGold for orthopedic bone defect repair, Tooth Shell for oral and plastic surgery applications, and Turui for neurosurgery, with over 50 varieties across orthopedics, stomatology, plastic surgery, and neurosurgery, sold to agents and terminal hospitals mainly in China. Founded in 2004 and headquartered in Beijing, China, the company operates a 10,000-level clean production workshop in the Zhongguancun Medical Device Park, Daxing District, and holds more than 50 Chinese patents plus over 10 overseas patents, including three NMPA Class III registrations and US FDA 510(k) clearances, with products used in over 200,000 clinical cases. In May 2021, Allgens listed on the Shanghai Stock Exchange STAR Market; in late 2023, it acquired 100% equity of German firm HumanTech Dental GmbH to expand dental implant capabilities, enhance transnational technology synergies, and broaden its product matrix for one-stop dental solutions.